News - Cyrano Therapeutics

Cyrano Therapeutics

Send Us a Message

Menu

About
Investors
Olfactory Dysfunction
Contact Us

Sensory Dysfunction News & Updates

Cyrano Therapeutics Secures $9M for Development of Treatment for Post-Viral Smell Loss

Cyrano Therapeutics Enrolls First Patient in Phase 2 Trial of CYR-064 for Post-Viral Smell Loss (Hyposmia) – Copy

Cyrano Therapeutics Enrolls First Patient in Phase 2 Trial of CYR-064 for Post-Viral Smell Loss (Hyposmia)

For more information about our upcoming clinical trials

contact Cyrano Therapeutics

The products and the information provided about specific products on or through this site have not been evaluated by the United States Food and Drug Administration and are not approved to diagnose, treat, cure, or prevent disease.

Menu

About
Investors
Ofactory Dysfunction
Contact Us

Powered By Planned Growth